Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mersana Therapeutics Inc (MRSN)
NASDAQ:MRSN
Holding MRSN?
Track your performance easily
MRSN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.07 - $6.28
Previous Close$2.12
Volume1.17M
Average Volume (3M)1.28M
Market Cap
$260.07M
Enterprise Value$233.38M
Total Cash (Recent Filing)$59.00M
Total Debt (Recent Filing)$32.31M
Price to Earnings (P/E)―
Beta1.77
Next Earnings
Nov 05, 2024EPS Estimate
-$0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.86
Shares Outstanding122,675,051
10 Day Avg. Volume1,351,040
30 Day Avg. Volume1,279,372
Standard Deviation0.37
R-Squared0.04
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)30.29
Price to Sales (P/S)8.36
Price to Cash Flow (P/CF)-2.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.80
Enterprise Value/Gross Profit6.33
Enterprise Value/Ebitda-2.33
Forecast
1Y Price Target
$5.80Price Target Upside173.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Mersana Therapeutics News
PremiumCompany Announcements
Mersana Therapeutics Releases Updated Corporate Presentation
Bulls Say, Bears Say
Bulls Say
Analyst RecommendationAnalyst's recommendation of OUTPERFORM and a price target of $8 per share.
Financial StabilityThe company has cash and equivalents of $162.7M which provides runway into 2026.
Pipeline ProgressMRSN announced continued pipeline progress with their next-generation Dolasynthen and Immunosynthen antibody-drug conjugate (ADC) platforms.
Bears Say
Competitive PositioningAnalyst remains cautious that this early XMT-1660 readout will show differentiation versus its three large pharma competitors.
Financial PerformanceEarnings per share reported at a loss of $0.20, missing the consensus estimate of a $0.17 loss.
Safety IssuesSafety signals included a 55% rate of severe adverse events and a 2% rate of fatal treatment-related adverse events.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
MRSN FAQ
What was Mersana Therapeutics Inc’s price range in the past 12 months?
Mersana Therapeutics Inc lowest stock price was $1.06 and its highest was $6.28 in the past 12 months.
What is Mersana Therapeutics Inc’s market cap?
Currently, no data Available
When is Mersana Therapeutics Inc’s upcoming earnings report date?
Mersana Therapeutics Inc’s upcoming earnings report date is Nov 05, 2024 which is in 47 days.
How were Mersana Therapeutics Inc’s earnings last quarter?
Mersana Therapeutics Inc released its earnings results on Aug 13, 2024. The company reported -$0.2 earnings per share for the quarter, missing the consensus estimate of -$0.167 by -$0.033.
Is Mersana Therapeutics Inc overvalued?
According to Wall Street analysts Mersana Therapeutics Inc’s price is currently Undervalued.
Does Mersana Therapeutics Inc pay dividends?
Mersana Therapeutics Inc does not currently pay dividends.
What is Mersana Therapeutics Inc’s EPS estimate?
Mersana Therapeutics Inc’s EPS estimate is -$0.17.
How many shares outstanding does Mersana Therapeutics Inc have?
Mersana Therapeutics Inc has 122,675,050 shares outstanding.
What happened to Mersana Therapeutics Inc’s price movement after its last earnings report?
Mersana Therapeutics Inc reported an EPS of -$0.2 in its last earnings report, missing expectations of -$0.167. Following the earnings report the stock price went down -4.93%.
Which hedge fund is a major shareholder of Mersana Therapeutics Inc?
Among the largest hedge funds holding Mersana Therapeutics Inc’s share is Woodline Partners LP. It holds Mersana Therapeutics Inc’s shares valued at 3M.
---
Mersana Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.80 (173.58% Upside)
$5.80 (173.58% Upside)
Hedge Fund Trend
Decreased
By 1.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.4%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
49.29%
12-Months-Change
Fundamentals
Return on Equity
-213.33%
Trailing 12-Months
Asset Growth
-42.40%
Trailing 12-Months
Company Description
Mersana Therapeutics Inc
Mersana Therapeutics, Inc. engages in the development and manufacture of antibody drug conjugates to improve patient outcomes in multiple oncology indications. Its lead product candidates are XMT-1522, which focuses on breast cancer and non-small cell lung cancer (NSCLC); and XMT-1536, which targets ovarian cancer and NSCLC. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.
---
MRSN Earnings Call
Q2 2024
0:00 / 0:00
---
MRSN Stock 12 Month Forecast
Average Price Target
$5.80
▲(173.58% Upside)
Technical Analysis
Arvinas Holding Company
―
Nektar Therapeutics
―
TRACON Pharmaceuticals
―
Kura Oncology
―
Best Analysts Covering MRSN
1 Year
1 Year Success Rate
4/12 ratings generated profit
1 Year Average Return
-4.47%
upgraded a buy rating 7 months ago
Copying David Nierengarten's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -4.47% per trade.
---